1. Academic Validation
  2. Chemoproteomics Enabled Discovery of Selective Probes for NuA4 Factor BRD8

Chemoproteomics Enabled Discovery of Selective Probes for NuA4 Factor BRD8

  • ACS Chem Biol. 2021 Nov 19;16(11):2185-2192. doi: 10.1021/acschembio.1c00256.
David Remillard 1 2 Nikolas A Savage 1 Alexia T Kedves 1 Joshiawa Paulk 1 Xin Chen 1 Francisco J Garcia 1 Michael J Romanowski 1 Patricia A Horton 1 Jason Murphy 1 Markus Schirle 1 Edmund M Harrington 1 Matthew B Maxwell 1 Helen Trinh Pham 1 Igor Maksimovic 1 Jason R Thomas 1 William C Forrester 1
Affiliations

Affiliations

  • 1 Novartis Institutes for BioMedical Research Inc., Cambridge, Massachusetts 02139, United States.
  • 2 Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts 02115, United States.
Abstract

Bromodomain-containing proteins frequently reside in multisubunit chromatin complexes with tissue or cell state-specific compositions. Recent studies have revealed tumor-specific dependencies on the BAF complex bromodomain subunit BRD9 that are a result of recurrent mutations afflicting the structure and composition of associated complex members. To enable the study of ligand engaged complex assemblies, we established a chemoproteomics approach using a functionalized derivative of the BRD9 ligand BI-9564 as an affinity matrix. Unexpectedly, in addition to known interactions with BRD9 and associated BAF complex proteins, we identify a previously unreported interaction with members of the NuA4 complex through the bromodomain-containing subunit BRD8. We apply this finding, alongside a homology-model-guided design, to develop chemical biology approaches for the study of BRD8 inhibition and to arrive at first-in-class selective and cellularly active probes for BRD8. These tools will empower further pharmacological studies of BRD9 and BRD8 within respective BAF and NuA4 complexes.

Figures
Products